A phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP Study

Gary R. Morrow(University of Rochester Medical Center), Shaker R. Dakhil(Cancer Center of Kansas), Charles E. Heckler(University of Rochester Medicine), Joseph A. Roscoe(University of Rochester), Pascal Jean‐Pierre(University of Miami), P. O. Schwartzenberger, Jeffrey K. Giguere(Prisma Health)
Journal of Clinical Oncology
May 20, 2008
10.1200/jco.2008.26.15_suppl.9512
Cited by 14

Related Papers

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
|JAMA Oncology|2017|913
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
|Journal of Clinical Oncology|1999|670
Prevalence, Demographics, and Psychological Associations of Sleep Disruption in Patients With Cancer: University of Rochester Cancer Center–Community Clinical Oncology Program
|Journal of Clinical Oncology|2009|564
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
|Journal of Clinical Oncology|2005|541